Phosphatidylserine in Medical Foods and FSMP: US and EU Regulatory Pathways for Buyers

Brands exploring phosphatidylserine for cognitive and neurological support eventually reach a regulatory fork: the same ingredient that sits comfortably in a US dietary supplement can also anchor a product positioned for patients under medical supervision — but only if the category rules are understood and the ingredient documentation is built for them.

The US "medical food" and the EU "food for special medical purposes" (FSMP) are related but not equivalent categories, and the difference changes what you must prove about the formulation — and about every kilogram of PS you buy. This article maps both frameworks and translates them into concrete supplier qualification requirements.

US Medical Food Framework: Where PS Fits

In the United States, a medical food is a food formulated to be consumed or administered enterally under physician supervision, for the specific dietary management of a disease or condition with distinctive nutritional requirements. Three consequences matter for PS buyers. No premarket approval exists, but the distinctive-requirements and physician-supervision criteria are strictly construed — a repositioned supplement with clinical language is a misbranded medical food. Medical foods are exempt from nutrition-labelling and health-claim rules that constrain supplements, yet must still meet facility registration and FSMA preventive-control requirements. And the label must state that the product is a medical food for a specific condition. PS has decades of published research behind it, but the burden sits on the formulation rationale: the product must answer a documented nutritional requirement of the disease population, not a general wellness claim.

EU FSMP Framework: A Different Logic

The EU treats FSMP as a distinct legal category under the Food for Specific Groups framework, with composition and information requirements set out in Commission Delegated Regulation (EU) 2016/128. FSMP are intended for the dietary management of people who cannot achieve sufficient intake through normal food, and are classified as nutritionally complete, nutritionally incomplete, or a supplementary stipulated diet. Unlike supplements, FSMP are not notified through food-supplement channels; placement runs through national competent authorities with varying procedures, and labelling must carry mandatory statements on intended use and physician supervision. For PS, the formulation narrative must show why dietary management requires the phospholipid at the proposed dose and why normal foods cannot supply it. Member-state practices differ, so market-by-market review is standard, not optional.

What the Stricter Categories Demand from the Ingredient Dossier

In both markets, the ingredient evidence bar rises well above supplement practice. Expect to compile: a full specification with identity, purity, and contaminant limits matched to the finished-product risk profile; a stability program showing the PS holds assay and oxidative quality through the claimed shelf life; allergen and processing-aid transparency covering the soy or sunflower raw material chain; and manufacturing documentation — GMP evidence, batch records on request, and change-control commitments. Analytical identity work should go beyond routine COA review, with method summaries and independent verification testing on incoming lots. The formulation rationale document — why PS, why this dose, why this population — is what converts an ingredient spec into a defensible category position, and every claim in it should trace back to a document in the dossier.

Supplier Qualification and Traceability for Clinical Nutrition

Supplier qualification for these projects mirrors pharmaceutical-style thinking. Audit the PS manufacturer directly or through a credible third party, covering solvent management, oxidation control, and allergen segregation. Require documented traceability from finished lot back to raw material intake. Contract for change notification with defined notice periods for process, raw material, and specification changes — reformulating a patient-facing product is far costlier than a consumer SKU. Agree on retention-sample and investigation-support terms in advance, because when a complaint or official sampling event occurs, response time is part of compliance. Finally, verify the supplier's regulatory posture in your target markets: a PS producer shipping into the EU with current food-safety certification and into the US with FDA facility registration shortens your dossier considerably.

Practical Launch Sequence for PS Medical Food and FSMP Projects

A workable sequence: define the target population and the distinctive-requirement rationale first, because it determines dose, format, and market. Select the PS grade on specification, stability data, and documentation scope — not price. Build the formulation with a contract manufacturer experienced in clinical nutrition formats, and lock the quality agreement before pilot production. Run stability from the first pilot batch. File or notify per market — EU procedures vary by member state, while the US path is guidance-based but enforcement-active. Keep the dossier living: change control, annual supplier review, and complaint trending feed it continuously. Projects in this category fail for documentation reasons more often than technical ones.

Часто задаваемые вопросы

Q: Is phosphatidylserine permitted in medical foods and FSMP?

A: Nothing in either framework prohibits phospholipid ingredients; the constraints are product-level. PS can be used if the formulation is designed around the documented nutritional requirements of the target population and the label, composition, and manufacturing evidence meet the category rules.

Q: Can one formulation serve both a US medical food and an EU FSMP?

A: Often yes at the formulation level, but the regulatory narratives differ. The US case rests on distinctive nutritional requirements and physician supervision; the EU case rests on dietary-management need under the FSMP classification and national procedures. Build one dossier with market-specific sections.

Q: What PS supplier documents should I request before starting a clinical nutrition project?

A: Full specification with methods, allergen and GMO statements, stability data on the commercial grade, food-safety certification and audit summaries, FDA facility registration or EU-market references, traceability policy, and a sample quality agreement with change-notification terms — before formulation work starts, because gaps discovered later reset the timeline.

Q: Do medical foods and FSMP still need ordinary food compliance?

A: Yes. Facility registration, preventive controls or HACCP, contaminant limits, and labelling baselines all continue to apply. The special category adds obligations on top; it does not replace the food-law floor.

Заключение

Medical foods and FSMP are demanding but realistic categories for phosphatidylserine — demanding because the argument shifts from "supported by studies" to "required by the patient population's condition," and every link in the ingredient chain must carry documentation weight. The US and EU frameworks differ in logic and procedure, so plan the market strategy before the formulation. A PS producer that delivers specification depth, stability evidence, traceability, and contractual change control turns your dossier into a submission package. Nutranexa supplies soy- and sunflower-derived PS with clinical-grade documentation and supports regulatory teams with the ingredient evidence their files require.

Источники

• U.S. FDA — Medical Foods Guidance Documents and Regulatory Information: https://www.fda.gov/food/guidance-documents-regulatory-information-topic-food-and-drug-administration-fda-staff-and-industry/medical-foods-guidance-documents-regulatory-information
• European Commission — Food for Specific Groups (incl. FSMP, Regulation (EU) 609/2013 and Delegated Regulation (EU) 2016/128): https://food.ec.europa.eu/food-labelling-and-nutrition/specific-groups_en
• NIH Office of Dietary Supplements — Phosphatidylserine consumer and background resources: https://ods.od.nih.gov
• PubMed — Peer-reviewed literature on phosphatidylserine and cognition: https://pubmed.ncbi.nlm.nih.gov/?term=phosphatidylserine+cognition
• U.S. FDA — Current Good Manufacturing Practice for Dietary Supplements and food facility requirements: https://www.fda.gov/food/current-good-manufacturing-practice-cgmp-dietary-supplements

Рекомендуемые дальнейшие действия

• Просмотрите Phosphatidylserine страница продукта.
• Сравнить Soy PS и Sunflower PS.
• Проверять производственное доказательство и Качество и НИОКР.